title: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of ezetimibe 10 mg administered with pravastatin in patients with primary hypercholesterolemia.
  
  
  RESULTS
  After dietary stabilization, 2-12 week screening/washout period, and 4-week, single-blind, placebo lead-in period, 538 patients with baseline LDL-C > or =3.8 to < or =6.5 mmol/l and TG < or =4.0 mmol/l were randomized to one of eight possible treatments administered daily for 12 weeks: ezetimibe 10mg; pravastatin 10, 20, or 40 mg; ezetimibe 10 mg plus pravastatin 10, 20, or 40 mg; or placebo. The primary efficacy endpoint was percent reduction in LDL-C from baseline to study endpoint for ezetimibe 10 mg plus pravastatin (pooled doses) compared to pravastatin alone (pooled doses) and ezetimibe alone. The combined use of ezetimibe and pravastatin resulted in significant incremental reductions in LDL-C and TG compared to pooled pravastatin alone (p<0.01). Coadministration therapy reduced LDL-C by 34-41%, TG by 21-23%, and increased HDL-C by 7.8-8.4%, depending on the dose of pravastatin. The combined regimen was well tolerated, with a safety profile similar to pravastatin alone and placebo.
  
  
  CONCLUSIONS
  When coadministered with pravastatin, ezetimibe provided significant incremental reductions in LDL-C and TG and was well tolerated with a safety profile similar to pravastatin alone.
authors.affiliation: Schering-Plough Research Institute, Kenilworth, NJ, USA. lorenzo.melani@spcorp.com
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Melani
authors.forename: Richard
authors.initials: R
authors.lastname: Mills
authors.forename: David
authors.initials: D
authors.lastname: Hassman
authors.forename: Robert
authors.initials: R
authors.lastname: Lipetz
authors.forename: Leslie
authors.initials: L
authors.lastname: Lipka
authors.forename: Alexandre
authors.initials: A
authors.lastname: LeBeaut
authors.forename: Ramachandran
authors.initials: R
authors.lastname: Suresh
authors.forename: Pabak
authors.initials: P
authors.lastname: Mukhopadhyay
authors.forename: Enrico
authors.initials: E
authors.lastname: Veltri
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D004311:Double-Blind Method; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014815:Vitamins / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D008055:Lipids; D014815:Vitamins; D000069438:Ezetimibe; D017035:Pravastatin